Study: Celecoxib can cause arrhythmias

Jan 15, 2008

U.S. medical researchers have determined the anti-inflammatory drug celecoxib (Celebrex) can adversely affect heart rhythm in fruit fly and rat models.

COX-2 inhibitors such as celecoxib have come under scrutiny due to adverse cardiovascular side-effects stemming from COX-2 reduction. But the new study found the drug-induced arrhythmia is independent of the COX-2 enzyme.

Satpal Singh and colleagues at the State University of New York at Buffalo tested various celecoxib doses on the heart rate of the fruit fly Drosophila. They found celecoxib reduced heart rate and increased beating irregularities.

The finding was a surprise, the researchers said, since Drosophila do not have COX-2 enzymes. Rather, the scientists said, celecoxib might directly inhibit the potassium channels that help generate the electric current that drives heartbeat.

Singh and colleagues note that since the arrhythmia effects bypass COX-2, it is unclear if other COX-2 inhibitors would yield similar results. They also stress it is too early to speculate on human effects.

The research appears in the Journal of Biological Chemistry.

Copyright 2008 by United Press International

Explore further: Merck ends development of Parkinson's disease drug

add to favorites email to friend print save as pdf

Related Stories

Galaxies fed by funnels of fuel

4 hours ago

(Phys.org) —Computer simulations of galaxies growing over billions of years have revealed a likely scenario for how they feed: a cosmic version of swirly straws.

Google eyes emerging markets networks

4 hours ago

Google has become deeply involved in a series of projects to build and operate wireless networks in emerging markets including sub-Saharan Africa and Southeast Asia, a report said Friday.

Recommended for you

Feds fight morning-after pill age ruling in NY

11 hours ago

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...

J&J expects 10-plus new drug applications by 2017

May 23, 2013

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Glaxo, US partnering to develop new antibiotics

May 22, 2013

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

User comments : 0

More news stories

Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

Feds fight morning-after pill age ruling in NY

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...